Trial Profile

An Open-Label, Phase 1b, Multi-Arm Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of Investigational Treatments in Combination With Standard of Care Immune Checkpoint Inhibitors in Patients With Advanced Melanoma

Status: Discontinued

Phase of Trial: Phase I

Latest Information Update: 06 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Plozalizumab (Primary) ; Tovorafenib (Primary) ; Vedolizumab (Primary) ; Ipilimumab; Nivolumab
Indications Malignant melanoma
Focus Adverse reactions
Sponsors Takeda Oncology

22 May 2018 Status changed from recruiting to discontinued.
02 Feb 2017 The time frame of primary endpoint has been changed from 30 days after last dose of study drug to 30, 60, and 90 days after last dose of study drug and different timeframe has added for different combination of drug i.e Baseline up to Week 9 for TAK-580 + nivolumab and TAK-202 (plozalizumab) + nivolumab; Baseline up to Week 7 for vedolizumab + nivolumab + ipilimumab.
25 Oct 2016 Planned End Date changed from 1 Sep 2018 to 1 Nov 2018.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com